Navigation Links
Sunridge to Introduce Their PNT Treatment for Glaucoma to Medical Personnel in India
Date:9/28/2010

FOUNTAIN HILLS, Ariz., Sept. 28 /PRNewswire/ -- Sunridge International (OTC Bulletin Board: SNDZ) said today that their treatment for glaucoma and ocular hypertension will be introduced in October to eye doctors and the medical community in India.

Presentations have been planned by its Indian distributors, New Amsterdam Marketing Corporation, in major cities from October 1 – 14.  The company's Pneumatic Trabeculoplasty (PNT), treatment is a cost-effective, non-invasive procedure designed to reduce pressure on the retinal nerve. The two-minute procedure, easily performed in a clinic or doctors office, is required only three or four times a year. It is a treatment regime that is especially valuable to patients in rural areas, where traditional medical facilities are limited.

Sunridge International, the developer and marketer of the PNT treatment, announced today that it's exclusive marketer in India, will be holding meetings to demonstrate the procedure to hundreds of medical personnel throughout the country.

The first presentations will be held at the (www.apos.in) conference in Hyderabad from October 1-3. This will be followed by meetings in Calcutta, Mumbai and Jaipur. The presentations will be led by Dr. Leo Bores, M.D.  Dr. Bores also will be holding private meetings over a two week period in India.

G. Richard Smith, CEO of Sunridge International, said the company was especially pleased to be able to bring the PNT procedure to India. "We are introducing our PNT equipment and treatments in many markets throughout the world, including the European Union countries, China and Latin America. But India is a very special place. It offers enormous opportunity for us."

"Working with New Amsterdam colleagues, we look forward to helping, perhaps, thousands of people suffering from glaucoma and ocular hypertension throughout the country. Often in the rural countryside, with a very poor population, glaucoma is left untreated. For many the cost of ongoing treatment is simply out of their reach. We strongly believe that PNT provides an answer to this problem, and gives people an opportunity for a safe, effective and affordable treatment.

"We will be giving the doctors and medical personnel attending the New Amsterdam presentations our fullest support and look forward to a long and mutually rewarding association with them."

Glaucoma is the second leading cause of blindness, affecting more than 70 million people worldwide. Studies completed over the last 10 years have proven that PNT is a safe effective and cost effective alternative treatment for glaucoma and ocular hypertension. The two-minute treatment has been developed, patented and distributed by Sunridge International's wholly-owned subsidiary, Ophthalmic International.(www.oi-pnt.com).CONTACT:Jeff Smith, Sunridge International   T:  +1-480-837-6165e-mail: info@sunridgeint.com website: www.sunridgeint.com MEDIA:Victor Webb, Marston Webb InternationalT: (212) 684-6601e-mail: marwebint@cs.com
'/>"/>

SOURCE Sunridge International
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Sunridge Announces Marketing Roll Out of PNT in the Dominican Republic
2. Sunridge Schedules European Meetings
3. Sunridge Ships First Order to the Middle East
4. The Heart, Diabetes, And Weight Loss Centers of New York Introduce the New Science of Metabolic Diagnosis and Weight Management
5. Quest Diagnostics Introduces ClariSure(TM) Test for Identifying Chromosome Abnormalities Associated With 85 Developmental Disorders in Children
6. Dr. Dello Russo Introduces the New EYE-Q Lasik
7. Caliper Life Sciences Introduces Drug Combination Services to Identify Synergistic Response of Compounds
8. Wedgewood Introduces Refresh(TM) Exchange-Program: Free Exchange of Expired Veterinary Compounded Medications Solves Key Industry Problem
9. CeloNova BioSciences Introduces a New Class of Coronary Stent: The CATANIA(TM) Coronary Stent System with NanoThin Polyzene(R)-F
10. Thermo Fisher Scientific Introduces Breakthrough in RNA-Interference Technology
11. Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... India , June 24, 2016 ... Needles Market by Type (Standard Pen Needles, Safety Pen ... Therapy (Insulin, GLP-1, Growth Hormone), Mode of Purchase (Retail, ... by MarketsandMarkets, This report studies the market for the ... expected to reach USD 2.81 Billion by 2021 from ...
(Date:6/24/2016)... June 24, 2016  Arkis BioSciences, a leading ... and more durable cerebrospinal fluid treatments, today announced ... Series-A funding is led by Innova Memphis, followed ... other private investors.  Arkis, new financing will accelerate ... the market release of its in-licensed Endexo® technology. ...
(Date:6/23/2016)... BEVERLY HILLS, Calif. , June 23, 2016 ... faced the many challenges of the current process. Many of ... option because of the technical difficulties and high laboratory costs ... would have to offer it at such a high cost ... to afford it. Dr. Parsa Zadeh , ...
Breaking Medicine Technology:
(Date:6/24/2016)... ... ... of Topricin and MyPainAway Pain Relief Products, join The ‘Business for a Fair Minimum Wage’ ... 2020 and then adjusting it yearly to increase at the same rate as the median ... floor does not erode again, and make future increases more predictable. , The company is ...
(Date:6/24/2016)... ... June 24, 2016 , ... EB Medicine presented its ... Emergency Medicine conference in Ponte Vedra Beach, FL. The awards honor the outstanding ... Medicine Practice and Pediatric Emergency Medicine Practice. , “With this award, we ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... Investment Group (TGIG), has initiated cultivation and processing operations at its production facility, ... Pahrump, Nevada. , Puradigm is the manufacturer of a complete system of proactive ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... National recruitment ... a life sciences executive with extensive sequencing and genomics experience, as Vice President of ... position, Ms. Hill will be responsible for leading the sales team in the commercialization ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... induced pluripotent stem (iPS) cells and other difficult to transfect cells, announces its ... The PluriQ™ G9™ Gene Editing System is a complete system for ...
Breaking Medicine News(10 mins):